Johnson & Johnson commits $500 million over four years to help end HIV, TB epidemics

Johnson & Johnson JNJ, +1.47% said Friday it is committing $500 million over four years to help end the epidemics of HIV and Tuberculosis. The New Brunswick, N.J.-based drug company said it will dedicate a team of researchers to leverage its scientific resources to accelerate the discovery of next-generation medicines and vaccines to complement current investments by governments.